Table 3. Association between metabolic syndrome (MetS) and overall survival in patients with proximal tumor in a univariate and multivariate analysis.

		Univariate analysis		Multivariate analysis
Factors	Number	Hazard ratio (95% confidence interval)	P value	Hazard ratio (95% confidence interval)	P value
Gender (Male/Female)	247/91	0.711(0.501–1.010)	0.057
age(<50/≧50)	72/266	1.371(0.932–2.018)	0.109
Tumor size (≤5 cm/>5 cm)	204/134	1.785(1.335–2.388)	<0.001	1.707(1.272–2.291)	<0.001
Degree of differentiation (Poorly differentiated, mucinous or signet ring adenocarcinoma/Moderate differentiated/Well differentiated)	233/88/17	0.781(0.596–1.024)	0.074
T stage(AJCC, 7th)(T1a/T1b/T2/T3/T4a/T4b)	21/4/46/17/213/37	1.009(1.000–1.018)	0.041	1.006(0.997–1.015)	0.222
N stage(AJCC, 7th)(N0/N1/N2/N3a/N3b)	126/52/78/62/20	1.036(1.025–1.046)	<0.001	1.035(1.025–1.046)	<0.001
Surgery type(radical/palliative)	312/26	1.380(0.857–2.221)	0.186
Angiolymphatic invasion(No/Yes)	322/16	1.805(0.980–3.323)	0.058
Chemotherapy (No/Yes)	211/127	0.879(0.651–1.188)	0.402
MetS (No/Yes)	286/52	0.595(0.381–0.930)	0.023	0.635(0.406–0.993)	0.047
Number of MetS Components			0.177
0	93	1(reference)
1	119	1.034(0.715–1.495)	0.860
2	74	1.173(0.788–1.748)	0.432
3	41	0.589(0.340–1.022)	0.060
4	11	0.758(0.274–2.101)	0.595
Single component meeting the criteria of MetS
BMI (No/Yes)	282/56	0.901(0.615–1.320)	0.591
Fasting plasma glucose or diabetes (No/Yes)	298/40	0.906(0.569–1.442)	0.677
Blood pressure (No/Yes)	202/136	0.951(0.708–1.278)	0.738
Triglycerides (No/Yes)	279/59	0.807(0.539–1.207)	0.296
HDL (No/Yes)	195/143	0.812(0.603–1.093)	0.169

Abbreviations: AJCC: American Joint Committee on Cancer, MetS: metabolic syndrome, BMI: body mass index, HDL: high density lipoprotein.